

Len W Seymour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9012243/publications.pdf>

Version: 2024-02-01

70
papers

4,299
citations

147801

31
h-index

118850

62
g-index

71
all docs

71
docs citations

71
times ranked

5211
citing authors

#	ARTICLE	IF	CITATIONS
1	Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination. <i>Nature Communications</i> , 2022, 13, 1182.	12.8	13
2	Optogenetically Engineered Neurons Differentiated from Human SH-SY5Y Cells Survived and Expressed ChR2 in 3D Hydrogel. <i>Biomedicines</i> , 2022, 10, 1534.	3.2	0
3	Tackling HLA Deficiencies Head on with Oncolytic Viruses. <i>Cancers</i> , 2021, 13, 719.	3.7	6
4	Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 1759-1776.	6.4	113
5	Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy. , 2021, 9, e001292.		34
6	Interfaces between cellular responses to DNA damage and cancer immunotherapy. <i>Genes and Development</i> , 2021, 35, 602-618.	5.9	61
7	Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus. <i>Molecular Therapy</i> , 2021, 29, 1668-1682.	8.2	33
8	Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 47-61.	4.4	8
9	Deregulation of HLA-I in cancer and its central importance for immunotherapy. , 2021, 9, e002899.		73
10	A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 152, 105456.	4.0	16
11	Development of a novel mammalian display system for selection of antibodies against membrane proteins. <i>Journal of Biological Chemistry</i> , 2020, 295, 18436-18448.	3.4	12
12	The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2020, 56, 115-123.	7.2	5
13	Convergent Evolution by Cancer and Viruses in Evading the NKG2D Immune Response. <i>Cancers</i> , 2020, 12, 3827.	3.7	12
14	Peptide-“TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. <i>Nature Biotechnology</i> , 2020, 38, 320-332.	17.5	210
15	External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase. <i>Cancers</i> , 2020, 12, 798.	3.7	11
16	Attenuation of the Hypoxia Inducible Factor Pathway after Oncolytic Adenovirus Infection Coincides with Decreased Vessel Perfusion. <i>Cancers</i> , 2020, 12, 851.	3.7	9
17	Use of Liquid Patient Ascites Fluids as a Preclinical Model for Oncolytic Virus Activity. <i>Methods in Molecular Biology</i> , 2020, 2058, 261-270.	0.9	5
18	Calcium Influx Caused by ER Stress Inducers Enhances Oncolytic Adenovirus Enadenotucirev Replication and Killing through PKC δ Activation. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 117-130.	4.4	7

#	ARTICLE	IF	CITATIONS
19	Polyvalent Diazonium Polymers Provide Efficient Protection of Oncolytic Adenovirus Enadenotucirev from Neutralizing Antibodies while Maintaining Biological Activity <i>In Vitro</i> and <i>In Vivo</i>. Bioconjugate Chemistry, 2019, 30, 1244-1257.	3.6	17
20	Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples. , 2019, 7, 320.		58
21	Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference. Cancer Gene Therapy, 2019, 26, 59-73.	4.6	17
22	Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction. Biomacromolecules, 2019, 20, 854-870.	5.4	32
23	Optogenetic control of iPS cellâ€derived neurons in 2D and 3D culture systems using channelrhodopsinâ€2 expression driven by the synapsinâ€1 and calciumâ€calmodulin kinase II promoters. Journal of Tissue Engineering and Regenerative Medicine, 2019, 13, 369-384.	2.7	22
24	Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells. Cancer Research, 2019, 79, 331-345.	0.9	27
25	Solid Tumor Immunotherapy with T Cell Engagerâ€Armed Oncolytic Viruses. Macromolecular Bioscience, 2018, 18, 1700187.	4.1	56
26	An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells. Cancer Research, 2018, 78, 6852-6865.	0.9	123
27	Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirusÂin murine cancer cells. , 2018, 6, 55.		16
28	Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators. Molecular Therapy - Oncolytics, 2017, 4, 18-30.	4.4	37
29	OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution. Molecular Therapy - Oncolytics, 2017, 4, 55-66.	4.4	17
30	Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer. Virology, 2017, 505, 162-171.	2.4	16
31	Oncolytic adenovirus expressing bispecific antibody targets Tâ€cell cytotoxicity in cancer biopsies. EMBO Molecular Medicine, 2017, 9, 1067-1087.	6.9	104
32	Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus. Molecular Therapy - Oncolytics, 2017, 5, 62-74.	4.4	40
33	Making Oncolytic Virotherapy a Clinical Reality: The European Contribution. Human Gene Therapy, 2017, 28, 1033-1046.	2.7	14
34	Combining Oncolytic Adenovirus with Radiationâ€A Paradigm for the Future of Radiosensitization. Frontiers in Oncology, 2017, 7, 153.	2.8	32
35	Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. , 2017, 5, 71.		113
36	Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. Bioconjugate Chemistry, 2016, 27, 2372-2385.	3.6	44

#	ARTICLE	IF	CITATIONS
37	Oncolytic viruses: finally delivering. British Journal of Cancer, 2016, 114, 357-361.	6.4	95
38	A PTential cause for the selectivity of oncolytic viruses?. Nature Immunology, 2016, 17, 225-226.	14.5	8
39	Under Pressure: Elevated Blood Pressure Enhances Targeting of Tumors by Oncolytic Viruses. Molecular Therapy, 2016, 24, 204-205.	8.2	4
40	Actin-resistant DNase I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth. Molecular Therapy, 2016, 24, 796-804.	8.2	29
41	Evolutionarily conserved primary TNF sequences relate to its primitive functions in cell death induction. Journal of Cell Science, 2016, 129, 108-120.	2.0	8
42	A Rapid-Response Humoral Vaccine Platform Exploiting Pre-Existing Non-Cognate Populations of Anti-Vaccine or Anti-Viral CD4+ T Helper Cells to Confirm B Cell Activation. PLoS ONE, 2016, 11, e0166383.	2.5	12
43	Improved <i>In Vitro</i> Human Tumor Models for Cancer Gene Therapy. Human Gene Therapy, 2015, 26, 249-256.	2.7	6
44	Macrophages and their interactions with oncolytic viruses. Current Opinion in Pharmacology, 2015, 24, 23-29.	3.5	10
45	In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nature Biotechnology, 2015, 33, 1201-1210.	17.5	362
46	Non-invasive and real-time passive acoustic mapping of ultrasound-mediated drug delivery. Physics in Medicine and Biology, 2014, 59, 4861-4877.	3.0	75
47	Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet, The, 2014, 383, 1129-1137.	13.7	689
48	Inertial cavitation to non-invasively trigger and monitor intratumoral release of drug from intravenously delivered liposomes. Journal of Controlled Release, 2014, 178, 101-107.	9.9	73
49	Cavitation-enhanced delivery of a replicating oncolytic adenovirus to tumors using focused ultrasound. Journal of Controlled Release, 2013, 169, 40-47.	9.9	56
50	Enhanced Tumor Uptake and Penetration of Virotherapy Using Polymer Stealthing and Focused Ultrasound. Journal of the National Cancer Institute, 2013, 105, 1701-1710.	6.3	98
51	Targeting of Liposomes via PSGL1 for Enhanced Tumor Accumulation. Pharmaceutical Research, 2013, 30, 352-361.	3.5	9
52	Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer. Nanomedicine, 2012, 7, 1683-1695.	3.3	23
53	Ultrasound-enhanced drug delivery for cancer. Expert Opinion on Drug Delivery, 2012, 9, 1525-1538.	5.0	100
54	Virotherapy â€“ cancer targeted pharmacology. Drug Discovery Today, 2012, 17, 215-220.	6.4	13

#	ARTICLE	IF	CITATIONS
55	Ultrasound-induced cavitation enhances the delivery and therapeutic efficacy of an oncolytic virus in an in vitro model. <i>Journal of Controlled Release</i> , 2012, 157, 235-242.	9.9	75
56	Cavitation-Enhanced Extravasation for Drug Delivery. <i>Ultrasound in Medicine and Biology</i> , 2011, 37, 1838-1852.	1.5	106
57	Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins. <i>Journal of Controlled Release</i> , 2011, 150, 196-203.	9.9	29
58	Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway. <i>Journal of Controlled Release</i> , 2011, 156, 381-389.	9.9	49
59	Oncolytic Virotherapy: Combining First-Rate Science with an Unmet Clinical Need. <i>Human Gene Therapy</i> , 2011, 22, 387-388.	2.7	0
60	Active Adenoviral Vascular Penetration by Targeted Formation of Heterocellular Endothelial-epithelial Syncytia. <i>Molecular Therapy</i> , 2011, 19, 67-75.	8.2	16
61	Adenovirus: Teaching an Old Dog New Tricks. <i>Human Gene Therapy</i> , 2011, 22, 1041-1042.	2.7	6
62	HPMA copolymers for masking and retargeting of therapeutic viruses. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 240-245.	13.7	78
63	Use of Tissue-Specific MicroRNA to Control Pathology of Wild-Type Adenovirus without Attenuation of Its Ability to Kill Cancer Cells. <i>PLoS Pathogens</i> , 2009, 5, e1000440.	4.7	115
64	Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. <i>Journal of Controlled Release</i> , 2009, 135, 152-158.	9.9	52
65	Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. <i>Blood</i> , 2009, 113, 1909-1918.	1.4	183
66	Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. <i>Journal of Gene Medicine</i> , 2008, 10, 280-289.	2.8	52
67	Virotherapy of Ovarian Cancer With Polymer-cloaked Adenovirus Retargeted to the Epidermal Growth Factor Receptor. <i>Molecular Therapy</i> , 2008, 16, 244-251.	8.2	81
68	Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer. <i>PLoS ONE</i> , 2008, 3, e2409.	2.5	158
69	Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. <i>Journal of Drug Targeting</i> , 2007, 15, 546-551.	4.4	45
70	Adenovirus Type 5 Interactions with Human Blood Cells May Compromise Systemic Delivery. <i>Molecular Therapy</i> , 2006, 14, 118-128.	8.2	138